8,665 Results

Orexigen Therapeutics sells assets to Nalpropion Pharmaceuticals, Inc..

 Added ago

Orexigen Therapeutics, Inc announced that it has entered into an asset purchase agreement with Nalpropion Pharmaceuticals, Inc. to sell substantially...

Keytruda + Alimta + carboplatin refiled with EMA for metastatic nonsquamous NSCLC.- Merck Inc.

 Added 11 hours ago

Merck Inc announced that following validation by the European Medicines Agency (EMA), the centralized review process has begun for the...

Positive data indicate that patients with unilateral knee OA pain treated with Zilretta experienced significant and sustained improvements in pain, function, and knee-related quality of life metrics.- Flexion Terpeutics.

 Added ago

Flexion Therapeutics, Inc. will present positive clinical data from a post-hoc analysis of patients with unilateral knee osteoarthritis (OA) pain...

PROMISE 1 phase III trial of ALD 403 show bennfits in longer treatment for episodic migraine.- Alder Biopharma.

 Added 11 hours ago

Alder BioPharmaceuticals announced new twelve-month data from its PROMISE 1 Phase III clinical trial of ALD 403 (eptinezumab) in episodic...

Post hoc analyses of Phase III studies of galcanezumab shows 50% reduction of migraine headache days.- Eli Lilly.

 Added 11 hours ago

Eli Lilly and Company announced results from a post-hoc subgroup analysis which demonstrated efficacy of galcanezumab in patients with episodic...

Study of Vercise DBS System at one year meets endpoint in Parkinsons disease-. Boston Scientific.

 Added 11 hours ago

Boston Scientific announced one-year data from the INTREPID study, the first and only prospective, double-blind, randomized, sham-controlled, multi-center study of...

NEOD 001 development is discontinued for AL Amyloidosis.-Prothena Corpn.

 Added 11 hours ago

Prothena Corporation plc has announced that the Company is discontinuing development of NEOD 001, an investigational antibody that was being...

Results of Phase III ARCTIC trial of durvalumab plus tremelimumab for NSCLC.- AstraZeneca

 Added 11 hours ago

AstraZeneca and MedImmune, its global biologics research and development arm, announced high-level results from the Phase III ARCTIC trial in...

Cancer genetic mutations not all treatable: System to rank relevance of mutations needed [ESMO Press Statement]

 Added 1 day ago

Cancer genetic mutations not all treatable: System to rank relevance of mutations needed [ESMO Press Statement]

Cancer genetic mutations not all treatable: System to rank relevance of mutations needed

Load more